TABLE 5.
Undifferentiated RTI nonpolymorphic treatment-selected mutations
| Position | Consa | TSM(s)b | No. of individuals |
|
|---|---|---|---|---|
| RTI treated | RTI naive | |||
| 3 | S | C0.3 | 19,241 | 42,633 |
| 16 | M | V0.4 | 19,884 | 43,640 |
| 31 | I | L1.6 | 21,490 | 45,863 |
| 33 | A | V0.2 | 21,573 | 46,050 |
| 34 | L | I0.7 | 21,582 | 46,129 |
| 54 | N | I0.1 | 28,794 | 51,991 |
| 58 | T | N0.2 S0.2 | 28,795 | 51,994 |
| 109 | L | I0.8 M0.1 V0.1 | 28,808 | 52,043 |
| 202 | I | T0.1 | 28,742 | 51,873 |
| 223 | K | Q2.1 E1.7 T0.5 P0.1 | 28,537 | 50,880 |
| 228 | L | R5.4 N0.1 I0.1 K0.1 | 28,148 | 50,071 |
| 302 | E | D0.3 | 12,507 | 20,464 |
| 312 | E | G0.4 | 10,935 | 17,751 |
| 341 | I | F1.4 | 6,671 | 5,802 |
| 394 | Q | S0.8 | 6,108 | 4,874 |
| 399 | E | G1.2 | 5,882 | 4,830 |
| 547 | Q | R3.6 | 473 | 2,559 |
a
Cons, consensus.
b
Nonpolymorphic treatment-selected mutations (TSMs) in boldface were previously reported as being associated with drug resistance (18).